EpiVax Introduces AI-Driven Tools for Enhanced Immunogenicity Prediction

EpiVax, Inc., based in Providence, Rhode Island, has recently announced the launch of new features powered by artificial intelligence for their exclusive in silico platform, ISPRI™. This innovative platform is dedicated to assessing the immunogenicity risk of biotherapeutic products and aims to provide manufacturers with vital insights into potential immunogenic responses.

The latest version includes an advanced model called JanusMatrix™ which has been fine-tuned to deliver a more precise immunogenicity score, reflecting the product's tolerance and improving the understanding of the immunogenicity risk landscape. Additionally, the platform features an updated model focused on predicting anti-drug antibodies (ADA), further enhancing the predictive capability of immunogenicity assessments.

For decades, EpiVax has been at the forefront of computational immunology, developing cutting-edge in silico algorithms to evaluate biotherapeutic sequences. These advancements are rooted in the core technologies of EpiMatrix® and JanusMatrix™, which analyze T lymphocyte epitope compositions and cross-conservation among humans to characterize immunogenicity risks related to specific sequences and immune tolerance. ISPRI™ integrates these tools with other rigorously validated methodologies, allowing a comprehensive risk assessment for both candidate sequences and impurities.

Enhanced Insights with JanusMatrix™ 2.1

The latest release, JanusMatrix™ 2.1, utilizes AI to refine the prediction of immune tolerance by weighing the cross-conservation of human epitopes. This enhancement results in a more accurate characterization of therapeutic epitopes and their tolerance profiles, which is crucial for developing safer biotherapeutics.

The JAX Immunogenicity Score

Building on the JanusMatrix 2.1 enhancements, EpiVax has developed a new immunogenicity score designed to more closely align with clinical outcomes. The adjusted EpiMatrix score, known as JAX, directly incorporates JanusMatrix’s tolerance potential into its calculations. This integrative approach fosters a deeper understanding of the intrinsic epitope density, providing a biologically informed assessment of immunogenicity risk across all therapeutic modalities.

ADA 2.2 for Antibody Prediction

Additionally, EpiVax's ADA model has been updated to version ADA 2.2. The improved model incorporates epitope-based measurements along with biophysical characteristics and action-mode criteria, providing another layer of evaluation for the immunogenicity risks of antibodies. Trained on a diverse set of clinical monoclonal antibodies, ADA 2.2 showcases a stronger correlation between predicted and observed immunogenicity, thereby enhancing the reliability of risk interpretation alongside the JAX scores.

These upgrades significantly bolster EpiVax’s capabilities in immuno-informatics, ensuring their offerings remain among the best in the field. The improvements make the in silico assessments of immunogenicity risk even more relevant and predictive, aligning with recent FDA initiatives aimed at promoting human-relevant methodologies (NAM) that help sponsors identify immune-related risks, maintain the value of their assets, and mitigate risks associated with development programs.

About EpiVax

EpiVax partners with biologics developers to manage immunogenicity risks throughout the product lifecycle. With deep scientific expertise in implementing advanced in silico analyses and cutting-edge in vitro approaches, the insights derived from actionable data help their partners reduce uncertainties, mitigate risks, and optimize resource allocations while devising regulatory strategies for safer and more effective treatments. For more information, please contact Sarah Moniz, the Director of Business Development and Marketing.

In conclusion, the advancements introduced by EpiVax are poised to transform the landscape of immunogenicity prediction and management in biotherapeutics, ultimately contributing to the development of safer and more effective biological products.